>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Supplied as 0.2 μm filtered solution in PBS, pH7.4 .
Contact us for customized product form or formulation.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (AM122) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (AM122)(Cat. No. S1N-M12A1) is more than 90% and the molecular weight of this protein is around 135-150 kDa verified by SEC-MALS.
Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H2) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (AM122) (Cat. No. S1N-M12A1) with a linear range of 0.08-2.5 ng/mL (QC tested).
Detection SARS-CoV-2 S protein RBD by Sandwich ELISA Assay.
Immobilized Anti-SARS-CoV-2 Spike S1 Antibody, chimeric mAb (Cat. No. S1N-M12A1) at 2 μg/mL (100 μL/well) can bind S protein RBD. And then add Anti-SARS-CoV-2 Spike S1 Antibody (Cat. No. S1N-M13A1) (Biotinylated in house) at 1:5000. Detection was performed using HRP-conjugated streptavidin with sensitivity of 25 pg/mL (Routinely tested).
Anti-SARS-CoV-2 Spike RBD Neutralizing antibody (Cat.No. S1N-M12A1) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD: ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 mutant and treated with the neutralizing antibody at increasing concentration. Percent inhibition is calculated based on the OD value.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $380.00
Price(USD) : $2500.00
Price(USD) : $25000.00
Price(USD) : $250000.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.